First, given the selection criteria of this study, there might be a selection bias towards more aggressive subtypes of breast cancer because in the past and also still today, patients with ER+ IBC might have been more likely to be treated like ER+ non-IBC, not receiving NACT. The gene discussed is ESR1; the disease is breast cancer.